Martin Faiss

Q: What is Martin Faiss email address?

Email Martin Faiss at mafaiss@aol.com and mfaiss@nvt-med.com. This email is the most updated Martin Faiss's email found in 2026.

Q: How to contact Martin Faiss?

To contact Martin Faiss send an email to mafaiss@aol.com or mfaiss@nvt-med.com. (updated on February 24, 2025)

Director Clinical Affairs at New Valve Technology | Stuttgart Region

About Martin Faiss

Martin Faiss currently serves as the Director of Clinical Affairs at New Valve Technology, where he plays a pivotal role in advancing innovative vascular and coronary medical devices. In this capacity, he oversees all clinical activities related to international clinical studies, ensuring that projects adhere to rigorous regulatory standards such as ISO 14155 and meet the highest quality benchmarks. His expertise in clinical trial management, protocol development, and CRO oversight enables him to coordinate complex multi-center studies efficiently, facilitating the successful evaluation of new therapies for critical limb ischemia, claudication, and peripheral vascular disease.

At New Valve Technology, Martin's strategic leadership is instrumental in driving the company's R&D initiatives forward. He collaborates closely with cross-functional teams to design and implement clinical protocols that generate robust evidence for device safety and efficacy. His deep understanding of vascular indications, including superficial femoral artery (SFA) interventions, allows him to optimize clinical pathways and improve patient outcomes. Furthermore, Martin's background as a qualified biologist and his experience in medical device sales and CRO management provide him with a comprehensive perspective on the entire clinical development lifecycle.

His proactive approach to clinical research, combined with his organizational skills and self-motivation, ensures seamless execution of international clinical trials. By leveraging his expertise in vascular indications and clinical research, Martin Faiss continues to contribute significantly to the advancement of minimally invasive therapies, ultimately aiming to improve the quality of life for patients suffering from peripheral arterial diseases.

Martin Faiss Work